Catridecacog

Drug Overview

Catridecacog is a highly specialized medication within the field of hematology, representing a major advancement in the treatment of rare bleeding disorders. As a Biologic medication, it is engineered in a laboratory to mirror the natural proteins found in human blood. For patients living with a severe, lifelong bleeding risk due to a missing coagulation protein, this treatment provides a reliable and life-saving safety net.

Classified as a Coagulation Factor XIII (Recombinant) therapy, catridecacog replaces a specific missing puzzle piece in the blood’s clotting system. By providing this missing factor, it allows patients with a rare genetic deficiency to form stable blood clots and live without the constant fear of sudden, life-threatening hemorrhages.

• Generic Name: catridecacog
• US Brand Names: Tretten
• Drug Category: Hematology
• Drug Class: Coagulation Factor XIII (Recombinant)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA-approved for routine prevention (prophylaxis) of bleeding in adults and children with congenital Factor XIII A-subunit deficiency.

What Is It and How Does It Work? (Mechanism of Action)

To understand how catridecacog works, you have to look at the final stages of how the body stops a bleed. When a blood vessel is injured, the body triggers a “coagulation cascade”—a domino effect of proteins activating each other to form a clot.

At the end of this cascade, a protein called fibrin forms a web to plug the hole. However, this initial fibrin web is weak and easily broken. This is where Factor XIII comes in. Factor XIII acts as a “molecular glue.” Once activated by thrombin (another clotting enzyme), Factor XIII cross-links the fibrin strands, weaving them tightly together to create a tough, stable blood clot that stops the bleeding and allows the tissue to heal.

Normal Factor XIII is made of two parts: the A-subunit (the active glue) and the B-subunit (the carrier that protects the A-subunit). Patients with congenital Factor XIII A-subunit deficiency are missing the active “glue” portion due to a genetic mutation. Because their blood clots break down too easily, they are at an extreme risk for severe bleeding, including spontaneous bleeding into the brain, joints, and muscles.

Catridecacog acts as a precise Targeted Therapy. It is an exact laboratory-made replica of the human Factor XIII A-subunit. When infused into the patient’s bloodstream, it binds to the patient’s existing B-subunits. Once an injury occurs, the drug activates and cross-links the fibrin web, stabilizing the clot and significantly reducing the risk of hemorrhage.

FDA-Approved Clinical Indications

Primary Indication

Catridecacog is primarily indicated for the routine prophylaxis (prevention) of bleeding in patients with congenital Factor XIII A-subunit deficiency. In this hematology category, it is used as a lifelong replacement therapy. By receiving regular infusions, patients maintain enough of the Factor XIII protein in their blood to prevent spontaneous bleeding episodes and protect their joints and vital organs from hemorrhage-induced damage.

Other Approved & Off-Label Uses

Because this drug is a highly specific Targeted Therapy designed for one exact genetic mutation, its uses are very narrow.

• Approved uses: It is strictly approved for the prevention of bleeding in congenital Factor XIII A-subunit deficiency.
• Off-Label uses: * Management of acute bleeding episodes or surgical bleeding in patients with known Factor XIII A-subunit deficiency.
  • Note: It is strictly NOT intended for use in patients with congenital Factor XIII B-subunit deficiency, as the drug requires the B-subunit to function properly in the body.

Dosage and Administration Protocols

Catridecacog is administered as an intravenous (IV) infusion. The dosage is based on the patient’s body weight, and the treatment schedule is typically once a month, which offers patients a manageable routine compared to other bleeding disorder treatments that require weekly doses.

Important Adjustments:

• Breakthrough Bleeding Adjustments: If a patient experiences breakthrough bleeding while on the standard 35 IU/kg monthly dose, the physician may adjust the dose up to a maximum of 40 IU/kg, or shorten the frequency to every 21 days.
• Renal/Hepatic Insufficiency: There are no specific dose adjustments required for patients with kidney or liver impairment, but physicians will monitor these patients closely.
• Weight-Based Dosing: Because the dose is calculated by weight (IU/kg), growing children and patients who experience significant weight changes must have their doses recalculated regularly.

Clinical Efficacy and Research Results

Clinical research from 2020 to 2026 continues to support the profound efficacy of catridecacog in preventing life-threatening bleeds. In pivotal clinical trials, patients receiving routine prophylaxis with catridecacog experienced a remarkable reduction in bleeding events.

Data shows that over 90% of patients treated with the standard monthly dose of catridecacog experienced an annualized bleeding rate (ABR) of zero for spontaneous bleeding requiring treatment. This means the vast majority of patients lived completely free of sudden, unprovoked bleeds. Furthermore, pharmacokinetic studies show that a monthly infusion successfully maintains target trough levels (the lowest level of the drug in the blood just before the next dose) above the critical threshold required to prevent severe hemorrhage.

Safety Profile and Side Effects

Black Box Warning

Catridecacog does not have an FDA Black Box Warning.

Common side effects (>10%)

Most patients tolerate this Biologic very well. When side effects do occur, they are generally mild and include:

• Headache
• Pain in the extremities (arms and legs)
• Injection site reactions (mild pain or redness where the IV was placed)

Serious adverse events

• Hypersensitivity and Anaphylaxis: Severe allergic reactions, including rash, hives, chest tightness, and difficulty breathing, can occur with any IV protein product.
• Thromboembolic Events (VTE/Thrombosis): Because the drug promotes clot stability, there is a rare risk of forming unwanted blood clots, especially if the patient has other risk factors for thrombosis.
• Neutralizing Antibodies (Inhibitors): The body’s immune system may mistakenly identify the recombinant protein as an invader and create antibodies against it. This neutralizes the drug, making it ineffective and increasing the risk of severe bleeding.

Management Strategies

If a severe allergic reaction occurs during infusion, the infusion must be stopped immediately, and emergency medical treatment (such as epinephrine and antihistamines) should be administered. If a patient begins experiencing frequent breakthrough bleeds, the doctor will order a blood test to check for neutralizing antibodies. If antibodies are present, alternative bypassing therapies may be required.

Research Areas

Current research in severe hematologic complications is exploring the broader roles of Factor XIII. Because Factor XIII is vital not only for blood clotting but also for tissue repair and bone biology, researchers are investigating if maintaining higher baseline levels of Factor XIII can improve wound healing after major surgeries or trauma. Additionally, early-phase studies are looking into gene therapy solutions for Factor XIII deficiency, which could one day offer a permanent cure, removing the need for monthly IV infusions entirely.

Disclaimer: Studies exploring whether higher Factor XIII levels improve postoperative or trauma-related wound healing are still investigational and not yet proven as a routine clinical strategy. Gene therapy approaches for Factor XIII deficiency remain in development and are not yet established as a permanent cure in standard clinical practice.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting therapy, several baseline diagnostics are required:

• Factor XIII Activity Assay: To confirm the severe deficiency (usually less than 1% activity).
• Subunit Testing: To confirm the patient specifically has an A-subunit deficiency, not a B-subunit deficiency.
• Standard Coagulation Studies: Interestingly, standard clotting tests like PT/INR and aPTT are usually completely normal in Factor XIII deficiency.
• Complete Blood Count (CBC): To ensure platelets and red blood cells are at healthy baseline levels.

Precautions during treatment

• Monitor for Clots: Patients and providers must be vigilant for signs of deep vein thrombosis (DVT) or pulmonary embolism, such as sudden leg swelling, chest pain, or shortness of breath.
• Track Bleeding: Patients should monitor for any unusual bruising, prolonged bleeding from minor cuts, or severe headaches, which could indicate the development of neutralizing antibodies.

“Do’s and Don’ts” List

• DO keep a precise calendar of your infusion dates. Consistency is key to preventing breakthrough bleeds.
• DO wear a medical alert bracelet stating you have Congenital Factor XIII deficiency and require specific replacement therapy.
• DO maintain a detailed log of any minor or major bleeding events to share with your hematologist.
• DON’T take over-the-counter NSAIDs (like aspirin, ibuprofen, or naproxen) without consulting your doctor, as these medications interfere with platelet function and increase bleeding risk.
• DON’T skip doses even if you feel perfectly healthy; the medication prevents bleeds before they start.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The information provided in this guide is not intended to diagnose, treat, cure, or prevent any disease without the direct supervision of a licensed physician. Always consult your hematologist or healthcare team regarding your specific medical condition, treatment options, and any side effects you may experience.